Evidence mapPaperPMID 37139804Full record

ReviewPharmaceuticals (Basel, Switzerland)2023

Pharmacological Treatments and Natural Biocompounds in Weight Management.

Amin Gasmi, Pavan Kumar Mujawdiya, Amine Nehaoua, Mariia Shanaida, Yuliya Semenova, Salva Piscopo, Alain Menzel, Volodymyr Voloshyn, Olena Voloshyn, Volodymyr Shanaida and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 6 countries.

Amin GasmiSociété Francophone de Nutrithérapie et de Nutrigénétique Appliquée, 69100 Villeurbanne, France.ORCID 0000-0003-2165-8373
Pavan Kumar MujawdiyaInochi Care Private Limited, New Delhi 110017, India.
Amine NehaouaResearch Department, Precision Health International, Ain Oulmene 19200, Algeria.
Mariia ShanaidaI. Horbachevsky Ternopil National Medical University, 46001 Ternopil, Ukraine.ORCID 0000-0003-1070-6739
Yuliya SemenovaNazarbayev University School of Medicine, Astana 010000, Kazakhstan.ORCID 0000-0003-1324-7806
Salva PiscopoDepartment of Nutritional Research and Development, Nutri-Logics SA, 9990 Weiswampach, Luxembourg.
Alain MenzelLaboratoires Réunis, 6131 Junglinster, Luxembourg.
Volodymyr VoloshynI. Horbachevsky Ternopil National Medical University, 46001 Ternopil, Ukraine.
Olena VoloshynTernopil Volodymyr Hnatiuk National Pedagogical University, 46027 Ternopil, Ukraine.
Volodymyr ShanaidaTernopil Ivan Puluj National Technical University, 46001 Ternopil, Ukraine.
Geir BjørklundCouncil for Nutritional and Environmental Medicine (CONEM), 8610 Mo i Rana, Norway.ORCID 0000-0003-2632-3935
I.Horbachevsky Ternopil National Medical University · UACare India · INNazarbayev University · KZSociété Francophone d’Arthroscopie · FRTernopil Ivan Pului National Technical University · UATernopil Volodymyr Hnatiuk National Pedagogical University · UAThe Research Council of Norway · NOUniversity Ferhat Abbas of Setif · DZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The obesity pandemic is one of society's most urgent public health concerns. One-third of the global adult population may fall under obese or overweight by 2025, suggesting a rising demand for medical care and an exorbitant cost of healthcare expenditure in the coming years. Generally, the treatment strategy for obese patients is largely patient-centric and needs dietary, behavioral, pharmacological, and sometimes even surgical interventions. Given that obesity cases are rising in adults and children and lifestyle modifications have failed to produce the desired results, the need for medical therapy adjunct to lifestyle modifications is vital for better managing obesity. Most existing or past drugs for obesity treatment target satiety or monoamine pathways and induce a feeling of fullness in patients, while drugs such as orlistat are targeted against intestinal lipases. However, many medications targeted against neurotransmitters showed adverse events in patients, thus being withdrawn from the market. Alternatively, the combination of some drugs has been successfully tested in obesity management. However, the demand for novel, safer, and more efficacious pharmaceutical medicines for weight management does exist. The present review elucidates the current understanding of the available anti-obesity medicines of synthetic and natural origin, their main mechanisms of action, and the shortcomings associated with current weight management drugs.

Indexed as

metabolic syndromenatural compoundsobesitysynthetic drugs

Identifiers

PMID37139804
PMCPMC9962258
OpenAlexW4318482825

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.